Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes – 8)

Next Previous
X
Search
Trial Profile

Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes – 8)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AWARD-8
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 01 Apr 2022 Results of post-hoc pooled analysis of six studies (AWARD-1, -2, -3, -6, -8 and -9) assessing association between treatment with dulaglutide and glycaemic variability in adult patients with type 2 diabetes mellitus, published in the Diabetes, Obesity and Metabolism.
    • 16 Jun 2020 Results of post-hoc analysis assessing GV in people with type 2 diabetes, treated with once-weekly dulaglutide (DU), and not receiving any concomitant insulin treatment presented at the 80th Annual Scientific Sessions of the American Diabetes Association
    • 05 Jun 2018 Results of a post-hoc analysis of AWARD-1, AWARD-5, AWARD-8 and AWARD-9 clinical trials (n=1499) assessing effects of dulaglutide versus placebo on liver and glycaemic/metabolic measurements, published in the Diabetic Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top